Adding Mitral Valve Annuloplasty to Surgical Revascularization Does Not Benefit Patients With Functional Ischemic Mitral Regurgitation⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.  by Jones, Robert H.
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dding Mitral Valve
nnuloplasty to Surgical
evascularization
oes Not Benefit
atients With Functional
schemic Mitral Regurgitation*
obert H. Jones, MD, FACC
urham, North Carolina
ruth reflected in 2 common-but-conflicting aphorisms
ust coexist in dynamic tension to produce favorable
utcomes in cardiac surgical patients: “fix everything while
ou are there” must be balanced with “perfect is the enemy
f good” to do all but not more than is needed for the
elfare of the patient. Fixing a leaking heart valve while one
s already performing coronary artery bypass grafting
CABG) does not seem like excessive striving for perfection.
See page 2191
owever, the article by Mihaljevic et al. (1) in this issue of the
ournal reports mitral valve annuloplasty produced no notice-
ble benefit for 54 of 290 patients undergoing mitral valve
nnuloplasty concomitantly with CABG when compared with
4 patients propensity matched for similar baseline character-
stics from the concurrent 100-patient cohort who received
nly CABG. Do conclusions from these 108 of the 390
atients with 3 and 4 mitral regurgitation identified on an
nitial echocardiogram now forever end the long-standing
ebate about the value of adding mitral valve annuloplasty to
ABG in patients with functional ischemic mitral regurgita-
ion? Could analysis of only 38 deaths occurring over the
ourse of 12 years in these 54 propensity-matched pairs of
atients possibly justify the definitive title of this editorial? Can
eaky valves possibly be safely left in the hearts of patients? The
nswers are yes and no to these questions. Implications of the
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Surgery, Duke University Medical Center/Duke Clinical
esearch Institute, Durham, North Carolina. The author is the principal investigatord
f the National Institutes of Health-sponsored Surgical Treatment for Ischemic Heart
STICH) Failure Trial.wo major author-defined limitations must be considered
efore accepting their conclusion as definitive.
imitation of an Observational Study
xperienced authors know that the publication of an observa-
ional study in any major journal requires an explicit confession
hat the study was not randomized. Neither manuscript re-
iewers nor journal editors appear to seriously expect the
andomized study to occur in their lifetimes. Therefore, only a
imple statement of need appears to maintain the scientific
tatus of the journal while not encumbering authors with
nnecessary work to propose the design of a randomized trial
uggested by the results of their observational study. Results of
his observational study would support proposing a random-
zed clinical trial addressing the hypothesis that “not adding
itral valve annuloplasty to CABG increases the 6-year
urvival of patients with ischemic cardiomyopathy and 3 or
 mitral regurgitation.” A feasibility estimate using the 6%
bsolute, but statistically insignificant, 6-year mortality advan-
age of not adding mitral valve annuloplasty to CABG suggests
hat at least 1,200 patients would need to be randomized and
ollowed for a mean of 6 years to demonstrate a 6% mortality
ifference with a 90% statistical power. Neither the National
nstitutes of Health nor purveyors of mitral annuloplasty rings
ould reasonably be expected to provide the $30 to $50 million
equired to complete this study. An alternate hypothesis likely
o be more attractive to medical device companies would be
adding mitral valve annuloplasty to CABG reduces short-
erm mortality.” However, the statistically insignificant (Table
1 in Mihaljevic et al. [1]) 5% excess death rate in the
ABG-only population at 1 year (Fig. 1B in Mihaljevic et al.
1]) could be readily explained away by 5% of CABG-only
atients for whom hemodynamic instability was the reason
tated for no mitral valve annuloplasty. The title of this
ditorial comment states the most rational hypothesis to
dvocate for a more definitive clinical study. In a perfect world
n which cardiovascular specialists were passionate about only
ffering therapy of proven benefit to their patients and Centers
or Medicare & Medicaid Services was empowered by Con-
ress to withhold reimbursement for unproven therapies except
n the context of a randomized clinical trial, a prospective
andomized trial to test a no-benefit hypothesis could easily be
erformed using cost savings generated from funds now
xpended for mitral annuloplasty procedures of questionable
enefit. Given this unlikely scenario to fund a randomized trial
f equivalence, the Mihaljevic et al. paper (1), interpreted in
he context of 3 other observational studies on this topic (2–4)
hat failed to show benefit for adding mitral valve surgery to
ABG in ischemic cardiomyopathy patients with functional
itral regurgitation, answers “yes” to the question as to whether
leaky valves can possibly be safely left in the hearts of patients.”
imitation of Analysis by Operation Received
f cardiac surgeons still posted their own operations, the 3
ifferent titles posted to definitively describe the specific
o
c
v
a
l
t
p
p
A
m
o
p
o
a
r
c
o
c
o
c
f
t
b
t
f
p
w
a
e
o
C
a
w
s
W
o
g
a
p
M
p
t
r
u
a
m
a
s
u
c
b
e
m
s
“
a
C
A
c
r
i
s
o
w
d
r
j
e
w
a
p
C
i
p
t
o
t
o
o
t
e
I
s
t
d
s
s
s
a
h
b
g
s
t
R
D
N
R
1
2
3
4
2203JACC Vol. 49, No. 22, 2007 Jones
June 5, 2007:2202–3 Editorial Commentperation intended for each patient in the 390-patient
ohort would have been either CABG, CABG with mitral
alve annuloplasty, or CABG with possible mitral valve
nnuloplasty. The posting of a possible mitral valve annu-
oplasty would more accurately indicate the cardiac surgeon
o be at equipoise about addition of mitral valve annulo-
lasty to CABG in an individual patient than would
ropensity matching patients using baseline characteristics.
change in equipoise of the surgeon during operation
ight change any of the 3 operative titles into a decision for
r against mitral surgery. The institution of CABG typically
recedes mitral valve surgery so that good or bad events
ccurring early in the operation might weigh for or against
dditional surgery when the CABG is complete. Although
etention of the option to exercise surgical judgment and
hange an intended operation is ethical and necessary to
ptimize operative results, confounding of reported out-
omes can only be fully understood if operation-performed
utcomes can be compared with operation-intended out-
omes. Moreover, this analysis also must include all patients
or whom a different operation was performed other than
he one intended. Defining surgical cohorts retrospectively
y operation performed permits bias intentionally or unin-
entionally masking as surgical judgment to exclude patients
rom cohorts by changing the name of the operation
erformed. For example, a patient undergoing a CABG
ith mitral valve annuloplasty that failed intraoperatively so
s to require the mitral valve to be replaced would have been
xcluded in the Mihaljevic et al. (1) study by naming the
peration a mitral valve replacement. Patients intended for
ABG with or without mitral valve annuloplasty for whom
n SVR operation was added when the patient failed to
ean from cardiopulmonary bypass would be excluded by
urgical ventricular reconstruction in the operation name.
ithout availability of a clear preoperative statement of
peration intended, all clinical studies must define sub-
roups retrospectively by the operation received. Thereafter,
n inventory can be taken of reasons stated for the operation
erformed. The dominant reason patients reported by
ihaljevic et al. (1) did not receive a mitral valve annulo-
lasty was that mitral regurgitation appeared less severe to
he surgeon at operation than the 3 mitral regurgitation
eported on preoperative echocardiography. The 5 patients
ndergoing CABG who had hemodynamic instability noted
s the reason a mitral valve annuloplasty was not performed
ust have had a long and difficult CABG that made the
dditional ischemic time required to complete the mitral
urgery appear to be of questionable value. The constraint to
se postprocedure names to define the cohort whose out-
ome information will be used to discuss the potential
enefit of an operation with the same name with a preop-
rative patient introduces complex confounding of unknown
agnitude and direction that cannot be fully neutralized by
tatistical modeling. Therefore, if the answer to the question
can leaky heart valves possibly be safely left alone” is to be
nswered with certainty, the answer must be no.onclusions
lthough only required by study design in randomized
linical studies, preoperative intention to treat can be
ecorded equally easily for observational clinical studies. An
deal design for future observational or randomized clinical
tudies would begin with preoperative identification and
btaining consent for participation from potential patients
ho are made aware of their options for mitral valve surgery
uring CABG. At the point during the operation, when the
esponsible physician must decide whether consent given
ustifies study participation, the state of operating surgeon
quipoise would define the operation choices compatible
ith the preoperative consent obtained. For the mitral
nnuloplasty question, this decision time would occur with
atients on cardiopulmonary bypass after completion of the
ABG and immediately before making the left atrial
ncision to begin the mitral valve repair. If the patient had
reviously consented to randomized selection of options
hat now coincide with surgeon equipoise, the specific
peration intended would be defined by randomization. If
he patient consented to only participate in a registry or
bservational study, the rationale for selection of a specific
peration would be documented as the intention to treat,
hereby minimizing need for subsequent crossover based on
vents that might change equipoise for a specific procedure.
nsightful use of existing national cardiovascular databases
upplemented with a web-based method to trap intention to
reat intraoperatively now makes it logistically feasible to
evise prospective clinical studies that could be inexpen-
ively conducted on large numbers of patients. Until wide-
pread demand for true evidence stimulates cardiovascular
pecialists to participate in gathering definitive evidence, we
re left with imperfect but better evidence than we had
eretofore. Cardiovascular specialists who have previously
elieved all leaky valves should be fixed now should down-
rade their certainty to conclude that some valves probably
hould be fixed in certain patients who still remain difficult
o identify before the operation begins.
eprint requests and correspondence: Dr. Robert H. Jones,
uke Clinical Research Institute, P.O. Box 17969, Durham,
orth Carolina 27715. E-mail: jones060@mc.duke.edu.
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